BACKGROUND: Molecular testing for epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) fusion is routinely performed in patients with stage IV lung adenocarcinoma to assess their eligibility for targeted therapy. Fine-needle aspiration (FNA)-derived material frequently is the only pathologic material available. The identification of genomic aberrations in thyroid nodules from FNA smears may help stratify cancer risk and spare patients from a second surgery. In the current study, the authors tested nucleic acid extracted from the cytology smears of lung and thyroid carcinomas for simultaneous detection of single-nucleotide variant, insertion/deletion, and gene fusion using an RNA-based next-generation sequencing assay. METHODS: A total of 27 cases (17 lung and 10 thyroid carcinomas, the majority of which had known variants) were tested. Areas of interest were scrapped from stained smears using a scalpel. Total nucleic acid was extracted. Gene fusion and mutational analysis was performed using the Comprehensive Thyroid and Lung FusionPlex Assay. Data were analyzed using the analysis pipeline provided by the vendor. Eleven cases with available formalin-fixed, paraffin-embedded (FFPE) tissue were tested in parallel. RESULTS: Gene fusions were detected in 6 cases; common single-nucleotide variants in EGFR, RAS, and BRAF in 14 cases; and in-frame deletions within EGFR in 3 cases. A concordance rate of 100% was observed between FNA and FFPE tissue. CONCLUSIONS: Cytology preparations can be a reliable source for the detection of both DNA and RNA aberrations. The ability to simultaneously detect multiple types of genomic variants is crucial for patients with advanced cancer and maximizes the usefulness of cytology specimens. Cancer Cytopathol 2018;126:158-69.
INTRODUCTION
Molecular testing for epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) fusion is routinely performed in patients with stage IV lung adenocarcinoma to assess their eligibility for targeted therapy. The current guideline from the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) recommends that patients should be tested regardless of age, race, and smoking history. 1 Fine-needle aspiration (FNA) is commonly considered as the first diagnostic procedure and FNA-derived material is frequently the only pathologic material available for morphologic diagnosis, immunohistochemistry, and molecular studies. It is especially in these instances that cytology material becomes extremely valuable for patient management.
Likewise, in patients with thyroid nodules, FNA is an integral part of the clinical assessment as defined by the American Thyroid Association guidelines 2 due to its high sensitivity and specificity. Although the diagnosis and management of benign and malignant nodules usually is not problematic, nodules classified as follicular lesions of undetermined significance/atypia of undetermined significance (FLUS/AUS; Bethesda category III 3 are challenging for both the cytopathologist and clinician. Approximately one-third of the FNA specimens in the suspicious for follicular neoplasm category (SFN; Bethesda category IV 3 are benign hyperplastic nodules. The majority of SFN FNA specimens are found to be neoplasms on surgical resection but overall, only a minority of them are proven to be cancer on follow-up. [4] [5] [6] These nodules always carry a differential diagnosis of follicular adenoma, follicular carcinoma (FC), follicular variant of papillary thyroid carcinoma (FVPTC), and noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). 2, 7, 8 These patients usually undergo an initial lobectomy followed by completion thyroidectomy if the nodules are found to be malignant on histologic examination. Multiple groups have evaluated the usefulness of molecular tests on thyroid nodules of undetermined cytology. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Studies have shown that BRAF p.V600E mutation and RET-PTC fusion were highly specific in PTC and up to 40% of BRAF-positive FNA samples were reported to be indeterminate or nondiagnostic by cytology. 10, 11, [13] [14] [15] 18, 19 The studies by Niki- 19 Another group 20 reported a sensitivity of 70%, a specificity of 77%, a positive predictive value of 42%, and a negative predictive value of 91%. Both groups concluded that molecular findings in conjunction with morphology may improve diagnostic certainty and guide patient management. 19, 20 As increasing requests for molecular testing are made on FNA materials, cytopathologists play a critical role in patient-centered care and personalized medicine. 21 Traditionally, formalin-fixed, paraffin-embedded (FFPE) cell blocks were the only acceptable cytology material for molecular testing. A practical pitfall of using the cell block for testing is the inability to assess cellularity before block preparation, which often results in insufficient tumor cells for additional studies. The performance of cytology specimens for molecular testing has been reported, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] including a recent international multicenter trial 32 using reference cytology slides generated from cell lines with multiple mutations at various allele frequencies. NGS coupled with the digital, color-coded barcode technologies (NanoString technologies, Seattle, Washington) also demonstrated the potential to replace fluorescence in situ hybridization (FISH) and immunocytochemistry. 33 Current clinical testing usually requires a DNA-based test for the detection of single-nucleotide variants (SNVs) and insertion/deletions (indels), and FISH, immunohistochemistry, or reverse transcriptase-polymerase chain reaction (RT-PCR) for the detection of gene fusions. After morphologic diagnosis, especially if ancillary studies are performed, there frequently is not enough material left with which to perform multiple different types of tests. Using a molecular test that can identify multiple genomic variants simultaneously from a specimen obtained via a minimally invasive procedure is challenging but extremely important for patient management.
The objectives of the current study were to assess the usefulness of nucleic acid extracted from cytology smears for use with an RNA-based NGS assay to detect multiple types of genomic variants including SNVs, indels, and gene fusions simultaneously from lung and thyroid carcinoma. The concordance of test results from cytology preparations with available paired FFPE tissue and/or an alternative method was also compared.
MATERIALS AND METHODS
The current study contains data from a clinical test validation using archived materials. It was approved by the institutional research review committee at the study institution. No informed consent from patients was required.
Case Selection
FNA specimens, touch preparations, and SurePath (Becton, Dickinson and Company, Franklin Lakes, New Jersey) preparations (both Romanowsky-type and Papanicolaoustained slides) cases (27 total) were selected from specimens previously submitted for molecular and/or FISH testing from 2012 through 2017 (Table 1) . Cases with known positive molecular findings were preferentially selected for test validation purposes and 11 cases had paired FFPE surgical resection materials (10 cases) or cell block (1 case) available for comparison testing.
All cases were reviewed by 3 pathologists, including 2 cytopathologists, and the optimal slides and blocks were selected for testing. All cases except 1 (L-10; Table 2 ) had multiple slides available. L-10 was a pleural effusion specimen with only a single SurePath slide. In cases with only 1 slide available, digital images were archived before coverslip removal and only approximately 25% to 50% of the slide was used for nucleic acid extraction. The slide then was coverslipped again and archived.
For thyroid FNA specimens, 6 slides were prepared (3 air-dried and 3 fixed). For lung FNA specimens, the number of slides varied depending on the cellularity of the tumor observed at on-site adequacy evaluation. At least 1 to 3 cellular smears usually are prepared. For effusion specimens, a single SurePath slide usually is prepared and cell block will be made if immunohistochemistry studies are expected.
Thirteen of 17 lung cases had undergone prior FISH for ALK rearrangement. The thyroid cases had been tested previously for mutations, but none had been tested for gene fusions. The 4 mutation-negative thyroid cases were included based on the fact that the driver mutation and gene fusion in thyroid carcinoma usually are mutually exclusive. The mutation-negative cases therefore had a better chance of harboring fusions.
Nucleic Acid Isolation
Areas with the highest percentage of tumor cells and least amount of contaminating materials (nonneoplastic cells, debris, and mucin) were selected for testing.
One to 2 slides generally were enough for molecular testing. Areas of interest were circled on the slide (typically from 1-10 circled areas) and the corresponding areas were etched on the back of the side with a diamond tipped pen. The coverslip was removed with heat or xylene. The slide then was washed with xylene 5 times into 95% to 100% ethanol and briefly air dried. These steps were necessary to remove residual coverslip mounting media. 34 The area of interest was manually dissected using a razor blade. For FFPE cell blocks or tissues, 1 hematoxylin and eosinstained and 10 unstained sections (6 mm) were cut, and corresponding areas of tumor were marked and manually scraped from the slides using a razor blade. The specimen was deparaffinized using deparaffinization solution (Qiagen, Valencia, California). Total nucleic acid (TNA), which represented a pool of mixed DNA and RNA, was extracted from either specimen type using the RNeasy Original Article 
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FFPE mini kit (Qiagen) excluding the DNAase treatment step. Nucleic acid extraction was performed only once for all specimens and the extracted TNA was sufficient for both RNA-based and DNA-based applications. The concentration of nuclei acids was determined using the Qubit 2.0 fluorimeter (Life Technologies, Carlsbad, California), Qubit RNA HS Assay Kit, and the Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific, Waltham, Massachusetts). A relative assessment of the RNA quality was determined using the manufacturer's real-time PCR assay for a 113-base pair (bp) exon junction spanning RNA amplicon from the VCP gene, which is included in the Comprehensive Thyroid and Lung (CTL) FusionPlex Assay (ArcherDx, Boulder, Colorado). A cycle threshold (Ct) value < 30 is considered acceptable for subsequent testing. The quality of DNA was assessed using the Qubit 2.0 fluorimeter and the Qubit dsDNA HS Assay Kit. DNA libraries with concentrations <100 ng/mL gave low-quality sequencing results and thus sequencing usually was not performed.
RNA-Based NGS Assay for the Detection of SNVs, Indels, and Fusions
Total RNA (50-250 ng) was reverse transcribed to cDNA. Libraries were prepared using the CTL FusionPlex Assay for Illumina Platform (ArcherDx) following the manufacturer's protocol (see Zheng et al 35 for principle) and sequenced using MiSeq (Illumina, San Diego, California). Data were analyzed using the CTL Target Region File and vendor supplied software (Archer Analysis, version 5.0). A minimum of 5 reads with 3 unique sequencing start sites that cross the breakpoints was set as the cutoff value to indicate strong evidence of fusions. The Target Mutation file (a text file in VCF format which lists the specific variants of interest) was created and used for targeted variant analysis.
Determination of Limit of Detection of the CTL FusionPlex Assay
Due to the limited amount of material for the FNA specimens, the limit of detection for fusion transcripts was determined using RNA derived from an FFPE specimen that was positive for echinoderm microtubule-associated protein-like 4 (EML4)-ALK and previously obtained for the assay validation but not included in the current study. Fusion-positive RNA was serially diluted with a fusionnegative RNA specimen. Fusions with 3 unique start sites could be reliably detected. Similarly, RNA from an NRAS p.Q61L-positive cell line (HL-60, ATCC CCL240; American Type Culture Collection, Manassas, Virginia) was serially diluted with RNA from a negative cell line (H1975, ATCC CRL-1908; American Type Culture Collection) with comparable NRAS expression and was reproducibly detected down to 1.0% mutant allele frequency.
RT-PCR and Sanger Sequencing Confirmation
Primers flanking specific fusions were designed based on the EML4-ALK fusion breakpoint sequences identified (EML4ex13_F-GTGCAGTGTTTAGCATTCTTG and ALKex 20_R-GTAGTCGGTCATGATGGTCG) and used to perform reverse transcription using the I Script cDNA Synthesis Kit (Bio-Rad, Hercules, California) and 500 ng of RNA from the FNA specimen. The resulting cDNA (2 lL) was used for amplification with the fusion-specific primers and PCR amplification was performed according to the AmpliTaq Gold 360 Master Mix protocol (Thermo Fisher Scientific) provided by the manufacturer: 958C for 10 minutes followed by 35 cycles at 958C for 30 seconds, 588 for 30 seconds, 728C for 30 seconds, and 728C for 7 minutes. PCR products were analyzed on 2% agarose gel and subsequently analyzed by Sanger sequencing. Individual sequence was manually aligned against the identified NGS sequence and specific fusion breakpoints were confirmed.
DNA-Based Massively Parallel Sequencing
DNA-based NGS was performed using the same TNA extracted for the CTL FusionPlex assay and the Ion Torrent AmpliSeq Cancer Hotspot Panel v2 (Thermo Fisher Scientific) or a laboratory-developed NGS panel that included hot spots of 10 genes (EGFR, BRAF, KRAS, NRAS, HRAS, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [PIK3CA], KIT, PDGFRA, isocitrate dehydrogenase 1 [IDH1], and IDH2). The AmpliSeq assay was performed according to manufacturer's instruction using 10 ng of genomic DNA. The libraries were barcoded, clonally amplified, and sequenced on Ion S5XL (Thermo Fisher Scientific). The data from both were analyzed using the Ion Torrent Suite Software followed by a laboratorydeveloped pipeline. Both assays have an analytic sensitivity of 5% for SNVs and 10% for indels.
Fluorescence in Situ Hybridization
A laboratory-validated FISH assay was performed on FFPE sections for EML4-ALK fusion using the Vysis ALK
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Dual Break Apart FISH Probe (reference 06N38-020; Abbott Molecular, Lake Bluff, Illinois) according to the manufacturer's instructions. Tumor cells were considered positive when at least 1 set of orange and green signals were 2 signal diameters apart or when there was a single orange signal without a corresponding green signal in addition to fused and/or broken apart signals. A total of 50 tumor cell nuclei were scored. A sample was considered negative if <5 cells were positive (<10% of cells) and positive if 25 cells were positive (50% of cells). An equivocal classification occurred when 5 to 25 cells were positive and required a second reader to enumerate another 50 cells. The sample was considered positive if 15% of cells were positive (n 5 100) and negative if the positive cells accounted for <15% of the total cells (n 5 100).
RESULTS
Characteristics of Included Cases
A total of 27 cytology cases were used for molecular testing, which included FNA smears, touch preparations, and liquid-based preparations. Among them, there were 15 lung adenocarcinoma specimens (4 primary and 11 metastatic), 1 metastatic large cell neuroendocrine carcinoma of the lung specimen, 1 metastatic small cell carcinoma of the lung specimen, and 10 thyroid carcinoma specimens (6 PTCs and 4 FCs), as summarized in Table  1 . One case each of metastatic large cell neuroendocrine carcinoma of the lung and metastatic small cell carcinoma of the lung were included as negative controls for gene fusions.
Assessment of the Quality of Nucleic Acid Obtained from Cytology Specimens
In cytology specimens, the percentage of tumor cells ranged from 20% to 90% and the TNA yield ranged from 24.6 ng to 1026 ng for DNA and 88.2 ng to 2960 ng for RNA. The tumor content in paired FFPE tissue ranged from 20% to 80% and the TNA yield ranged from 205 ng to 2160 ng for DNA and from 1009 ng to 5440 ng for RNA. The quality control step was incorporated into the FusionPlex library preparation for assessing the amount of amplifiable RNA and predicting subsequent sequencing success. All specimens tested with a Ct value of <30 were successfully sequenced.
Detection of Genomic Variants by the CTL FusionPlex Assay
The CTL FusionPlex assay is an RNA-based targeted NGS panel that contains 17 genes commonly rearranged in lung or thyroid carcinomas but also includes targets for common SNVs, small indels, and splicing mutations and can be used to assess gene expression. The limit of detection for RNA fusion depends on the expression level of the fusion of interest, the number of targets in the assay, and the level of PCR duplication in the library. We could reliably detect gene fusions with 3 unique start sites with minimal tumor content of 20%.
Using this assay, we identified 3 different variants of EML4-ALK fusion in 4 cases of lung adenocarcinoma ( Table 2 ). All fusion breakpoints in the ALK gene were in exon (ex) 20. The fusion breakpoints in the EML4 gene included ex20, ex13, and ex8 (Table 2) . Two fusions were identified in thyroid carcinomas (Table 3) . A coiled-coil domain containing 6 (CCDC6)-RET fusion was identified in case PTC-1 from a patient who had a history of head and neck squamous cell carcinoma and had completed radiotherapy. A PAX8-PPARc fusion was found in a patient (case FC-1) with FC.
We also assessed the ability of the assay to identify hotspot mutations in genes commonly mutated in lung and thyroid carcinomas with no additional analysis. Common EGFR or KRAS mutations were detected in 11 of 17 cases of fusion-negative lung carcinomas (Table 2) . BRAF p.V600E or KRAS mutations were noted in 6 of 8 fusionnegative cases of PTC and FC (Table 3) .
Concordance of CTL FusionPlex-Detected Gene Fusions with FISH
Prior FISH results for ALK rearrangements were available in 13 of the 17 cases of lung carcinoma (Table 2 ). There was 100% concordance between the FISH and RNA findings. A representative ALK FISH-positive case (L-3) that had a sufficient amount of RNA also was confirmed by RT-PCR followed by Sanger sequencing. Visualization of gene fusions detected by the CTL FusionPlex assay was performed using the JBrowse 36 software (ArcherDx), which allows for visualization of the gene fusions and checking for fusion calls, and assists us in designing primers for RT-PCR confirmation. The genomic coordinates of the fusion transcript breakpoints were detected through the Archer Analysis pipeline (Tables 2 and 3) . Primer sets for PCR flanking the specific breakpoints were designed accordingly. Representative FISH (Fig. 1A) and RT-PCR (Fig. 1B) confirmation results for an ELM4-ALK fusion (case L-3) along with the aligned sequence for the fusion identified from NGS and subsequent Sanger sequencing confirmation (Fig. 1C) are shown in Figure 1 . The presence of CCDC6-RET and PAX8-PPARc fusion was confirmed by an earlier version of the CTL FusionPlex assay (the Archer FusionPlex Lung Thyroid Panel), which had 8 targeted genes, including ALK, RET, and PPARc, among others.
Concordance of CTL FusionPlex-Detected SNVs and Indels by DNA-Based NGS Assay
Using TNA extracted for the CTL FusionPlex assay, mutational analysis was performed using the Ion AmpliSeq Cancer Hotspot Panel v2 (Thermo Fisher Scientific) or a laboratory-developed smaller NGS panel; both are DNAbased assays that can detect SNVs and small indels in most commonly mutated genes of both tumor types. There was 100% concordance between mutations detected by the RNA-based CTL FusionPlex assay and the DNA-based NGS assays (Tables 2 and 3 ). Representative case of lung adenocarcinoma with a KRAS p.G13C mutation (L-11) and another case with an EGFR 15-bp deletion (L-8) are shown in Figure 2 .
Concordance of Cytology Preparations With FFPE Tissue
For 11 of the cases (3 lung adenocarcinomas, 5 PTCs, and 3 FCs of the thyroid), FFPE tissue was available for comparison. All results were concordant between these paired specimens (Tables 2 and 3 ). Figure 3 demonstrates 2 representative cases of PTC with the same fusion (CCDC6-RET) and mutation (BRAF p.V600E) detected in the FNA specimen and paired FFPE tissue.
DISCUSSION
In the era of personalized medicine, molecular oncology testing has become an integral part of patient care. Cytology material derived from either FNA or body fluid collection may be the only available tissue for morphologic and molecular studies, especially for patients with lung cancer who present at an advanced stage.
The clinical molecular laboratory that only uses FFPE cell block material from cytology specimens may be limiting their sources for tumor DNA and/or RNA and potentially requiring the patient to undergo additional procedures to obtain sufficient material. In contrast to some studies 12, 14, [16] [17] [18] [19] in which the molecular data were generated from dedicated passes collected into separate transport media rather than made into smears, a practical advantage of using the stained slides is that it allows for the direct visualization of specific abnormal cells for testing. The expert panel on molecular testing guidelines for lung adenocarcinoma used to recommend cell block over cytology smear for EGFR mutational analysis. 1 The revised working draft now recommends that either cell blocks or other cytologic preparations are suitable specimens for biomarker testing (https://www.iaslc.org). Genomic variants of different types often are found in the same tumor type and more extensive genetic profiling is requested on limited FNA material. 37 We explored the use of a laboratory-validated, RNA-based NGS assay for the detection of gene fusions from direct cytology smears. The unique characteristic of this assay is its ability to discover novel fusions without prior knowledge of the fusion partners. Another important advantage of this assay is the ability to simultaneously detect hotspot mutations in genes such as EGFR, BRAF, KRAS, NRAS, HRAS, ALK, ROS1, RET, and PIK3CA that are important in lung and thyroid carcinomas. The 27 cytology cases represented adenocarcinoma of the lung, PTC, and FC of the thyroid. All the fusions detected in the current study have been reported in the literature. The CCDC6-RET fusion is known to be associated with radiation-associated PTC, as was the case for the patient from case PTC-1, who developed PTC after radiotherapy for head and neck squamous cell carcinoma. Using the same assay, common SNVs and small deletions were detected in BRAF, KRAS, and EGFR, including coexisting tyrosine kinase inhibitor (TKI)-sensitizing and TKIresistant mutations (p.L858R and p.T790M in case L-9). The patient in case L-9 was a 54-year-old male who originally presented with a large right hilar mass and bone metastasis and subsequent brain metastasis 2 years later that was tested positive for a TKI-sensitizing EGFR mutation, p.L858R (allele frequency of 84%). The following year, he developed disease progression and a biopsy of a lung mass demonstrated the presence of a TKI-resistant p.T790M mutation (allele frequency of 66%) in addition to the preexisting p.L858R mutation (allele frequency of 84%). The patient initiated treatment with osimertinib and survived for an additional 5 months.
In the current study, all fusions detected by the CTL FusionPlex assay had prior FISH results from FFPE tissue or were confirmed by an alternative NGS-based assay. The presence of SNVs and indels was confirmed by a separate DNA-based NGS assay. There also was 100% concordance between the cytology preparation and FFPE tissue 
